Randomized trial · people
Semaglutide: 14.9% weight loss at 68 weeks in STEP 1
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In this large trial, adults without diabetes on weekly semaglutide plus a lifestyle program lost much more weight than those on placebo, and more of them stopped treatment because of gut side effects.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 1961
- Published
- 2021
- Journal
- N Engl J Med
What they tested
The team tested whether a once-weekly 2.4 mg semaglutide shot, added to a lifestyle program, helps adults with overweight or obesity lose weight.
How the study was done
A double-blind, randomized, placebo-controlled trial in 1961 adults without diabetes who had a BMI (body-mass index, weight relative to height) of 30 or more, or 27 or more with at least one weight-related health problem. People were assigned 2 to 1 to weekly semaglutide or placebo (a dummy shot) under the skin for 68 weeks, and both groups also got a lifestyle program.

Model. Individual results vary.
What they found
By week 68, body weight fell by 14.9% on average in the semaglutide group and by 2.4% in the placebo group, an estimated difference of 12.4 percentage points. In kg, the change was -15.3 kg with semaglutide and -2.6 kg with placebo. A loss of 5% or more was reached by 86.4% of the semaglutide group versus 31.5% on placebo, and a loss of 15% or more by 50.5% versus 4.9%. Nausea and diarrhea were the most common side effects, mostly mild to moderate and fading over time, and 4.5% on semaglutide stopped treatment due to gut side effects versus 0.8% on placebo.
What it doesn’t show
The trial ran 68 weeks and left out people with diabetes, so it does not show longer-term results or results in that group. It was funded by Novo Nordisk.
The paper
Wilding et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021.
The compound
More studies on Semaglutide
- CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5Randomized trial · people · 2026
- Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3Randomized trial · people · 2026
- Semaglutide (oral) did not slow early Alzheimer's in evoke trialsRandomized trial · people · 2026
- Semaglutide: 36% vs 0% hit glucose and weight goal in type 1 diabetesRandomized trial · people · 2025
- Semaglutide 25 mg pill: 13.6% weight loss at 64 weeks in OASIS 4Randomized trial · people · 2025
- Semaglutide: MASH resolved in 62.9% vs 34.3% on placebo at 72 weeksRandomized trial · people · 2025
- Every study on Semaglutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.